Organovo Holdings, Inc. (ONVO) reported details of 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis. The company said the study results showed statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. FXR314 was also found to be safe and well tolerated.
Keith Murphy, Organovo's Executive Chairman. "Given these exciting findings, we believe the data are supportive of further clinical development of FXR314 in MASH."
Shares of Organovo Holdings are up 27% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com